Abstract: One exemplary embodiment includes a friction material including a base including a plurality of fibers. The base including an engagement surface, and a plurality of binder particles and friction modifying particles at the engagement surface.

Abstract: A vehicle having a device that uses an input provided from a first hydraulic system to charge one or more other hydraulic systems. The first hydraulic system can be a vehicle brake system or a hydraulic system having an electrically operated pump. The hydraulic systems to be charged could include an engine lubrication system and/or a transmission hydraulic control system.

Abstract: A harmonic suppression system, including an interface connector is connected to a common end of a first differential SPMT switch; a control port of the first differential SPMT switch is connected to a control port of a second differential SPMT switch, and a gating throw end of the first differential SPMT switch is separately connected to one end of each LC trap network in a one-to-one correspondence; the control port of the second differential SPMT switch is connected to a baseband chip, each gating throw end of the second differential SPMT switch is separately connected to the other end of each LC trap network in a one-to-one correspondence, and a common end of the second differential SPMT switch is connected to the baseband chip; the baseband chip is connected to an antenna switch; and the antenna switch is connected to a antenna.

Abstract: A traffic switching method, a device, and a system where, a software-defined networking (SDN) controller acquires a first state of a target gateway, where the target gateway belongs to an SDN gateway group, the SDN gateway group is used to forward traffic that is transmitted between a first network node and a second network node, and multiple forwarding paths on which multiple gateways in the SDN gateway group are located form multiple equal-cost paths between the first network node and the second network node. The SDN controller sends an Address Resolution Protocol (ARP) entry to the target gateway according to the first state, and changes, of the multiple equal-cost paths, a metric value of a forwarding path on which the target gateway is located from an original value to a first value, where the first value is greater than the original value.

Abstract: Embodiments related to storing and utilizing information of a sink device for establishing communication. A source device retrieves the information of a previously connected sink device stored in the source device to reduce data exchanged during a handshaking operation. Information of the sink device not stored in the source device may be stored in the source device for future usage. The source device receives identification information of the sink device via a medium. The source device also searches for capabilities information associated with the identification information in the source device. In addition, the source device encodes the content for transmission to the sink device via the medium in a format compliant with capabilities of the sink device according to the capabilities information.

Abstract: The present invention relates to improved methods for antibody engineering, e.g., humanization. In particular, the disclosure provides a high-throughput antibody humanization process that can be automated by computer-implementation.

Abstract: Binding proteins that bind one or more of VEGF, PDGF and/or their receptors, including antibodies, CDR-grafted antibodies, humanized antibodies, binding fragments, fusion proteins, and bispecific or multispecific proteins thereof are disclosed. Also disclosed are methods of making and using the binding proteins.

Abstract: A harmonic suppression system, including an interface connector is connected to a common end of a first differential SPMT switch; a control port of the first differential SPMT switch is connected to a control port of a second differential SPMT switch, and a gating throw end of the first differential SPMT switch is separately connected to one end of each LC trap network in a one-to-one correspondence; the control port of the second differential SPMT switch is connected to a baseband chip, each gating throw end of the second differential SPMT switch is separately connected to the other end of each LC trap network in a one-to-one correspondence, and a common end of the second differential SPMT switch is connected to the baseband chip; the baseband chip is connected to an antenna switch; and the antenna switch is connected to a antenna.

Abstract: An address resolution method uniformly processing ARP broadcast packets by an address server to avoid broadcasting in the network, so that the occupied bandwidth is reduced. The method also includes storing by a network device and terminal address correspondence information of local and remote terminals in communication with one another, which reduces the size of the MAC table in the data center network, reduces the load of the network device, and improves the processing capabilities of the network device, so that it is possible to deploy a large layer-2 network to thereby solve real-time relocation problems of a virtual machine.

Abstract: Embodiments related to storing and utilizing information of a sink device for establishing communication. A source device retrieves the information of a previously connected sink device stored in the source device to reduce data exchanged during a handshaking operation. Information of the sink device not stored in the source device may be stored in the source device for future usage. The source device receives identification information of the sink device via a medium, The source device also searches for capabilities information associated with the identification information in the source device. In addition, the source device encodes the content for transmission to the sink device via the medium in a format compliant with capabilities of the sink device according to the capabilities information.

Abstract: Systems and methods may provide for a video encoder that reconstructs a video frame. A number of initial reconstructed macro block lines may be generated by encoding initial reconstructed macro block lines from a first buffer holding a current frame. The initial reconstructed macro block line may be placed in a FIFO buffer sized to hold the initial reconstructed macro block lines. An additional reconstructed macro block line can be generated by encoding the next line in the current frame using at least one reconstructed macro block line in the FIFO buffer. A re constructed macro block line pulled from the tail of the FIFO buffer maybe placed sequentially in a reference buffer. After all the number of lines in the current frame have been processed, the additional reconstructed macro block lines may be pushed onto the head of the FIFO buffer.

Abstract: The application discloses a method and a system for information synchronization between cloud storage gateways and a cloud storage gateway, to resolve a problem that an address obtained by a cloud storage gateway is usually a dynamic address or even a private address, and it is difficult to perform direct communication and impossible to perform directory synchronization. A cloud storage gateway obtains, from a cloud message queue of a cloud service provider, a directory distributed by another cloud storage gateway; and therefore, as long as the cloud storage gateway can communicate with the cloud service provider, directory synchronization can be implemented without a need of direct communication between the cloud storage gateways. Therefore, even through an address obtained by the cloud storage gateway is a dynamic address or a private address, directory synchronization is not affected.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: Disclosed are ink compositions for printing patterns on substrates having non-stick fluororesin coatings. The ink compositions are particularly useful for printing decorative patterns or markings on cookware or bakeware to provide aesthetic and/or functional effects. Also disclosed are coated substrates which comprise non-stick coatings having patterns. Further disclosed are methods of manufacturing the coated substrates comprising non-stick coatings having patterns.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: The present invention relates to improved methods for antibody engineering, e.g., humanization. In particular, the disclosure provides a high-throughput antibody humanization process that can be automated by computer-implementation.

Abstract: The invention provides methods of introducing diversity into antibody molecules comprising introducing or substituting at least one amino acid sequence in the CDR of the target antibody together with at least one amino acid in the FW region spanning the 3 amino acid adjoining the CRD on each side. The resulting diverse antibodies with variant CDRs and FW region sequences comprising diverse amino acid sequences are also described. These polypeptides regions, herein referred to as 3+CDR3+, that form the gist of the invention contribution described herein provide a flexible and simple source of sequence diversity that can be used as a source for expressing and identifying diverse antibodies or antigen binding polypeptides. Libraries comprising a plurality of these polypeptides are also provided. In addition, methods of and compositions for generating and using these polypeptides and libraries are provided.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.